Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAMILY
ChiCTR-IIR-17014036Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Fulvestrant maintenance with Capecitabine maintenance (2 arms). Primary endpoint: progression-free survival. Started May 2018; status: recruiting.
02
Drugs
fulvestrantcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-IIR-17014036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17014036.